Project: Research project

Project Details


Prostate cancer (CaP) is a major and growing health problem in America.
During the past ten years, a 63% increase in the detection of CaP has
occurred, with 122,000 cases currently detected annually. Due to the
aging of the American male and intensified screening procedures, this
figure win only continue to rise. Annually, there are 30,000 deaths
attributed in American to CaP. The overall goal of this program project
is the biological characterization of CaP which will allow individualized
treatment of this disease. Information obtained in this program project
should identify which patients with local disease need to be treated,
determine when treatment should be initiated, and decide which therapy is
most appropriate. Our hypothesis is that genetic abnormalities will be
found at either the RNA or DNA level that determine the natural history
of CaP. Studies will be conducted to identify and assess the prevalence
of these genetic abnormalities or their manifestation in benign,
premalignant, and malignant prostate tissue. By comparing the findings
in local and metastatic tumors, characteristics of tumors with metastatic
potential will be identified. By comparing the tumors that respond to
radiation therapy and those that fail to respond, guidelines for
selecting this form of therapy will become available. Similarly, for
patients with disseminated CaP, the local and metastatic tumor will be
compared at the time of initiating hormonal therapy and at the time of
hormonal failure in order to evaluate the ability to predict these events
by analysis of the human androgen receptor. The information gained will
be compared and contrasted to the findings in patients with localized
disease. The identified differences will allow classification of tumors
into high and low metastatic potential groups. The program will include
the standard staging and pathological information as well as urinary PSA
studies, ploidy studies by flow and image analysis, and morphometric
studies by image analysis. Molecular studies will focus on hAR, nm23,
p53, and Rb-1 expression. The studies will be carried out under three
separate projects: the flow and molecular studies at Davis, the image
studies in Colorado. Tissue for these studies will come from Davis, St.
Joseph Mercy Hospital, and Howard University. Thus, while each
laboratory will produce its separate set of results, all studies will be
accomplished on the same tissue obtained from closely characterized
patients. The results will be centralized so that maximum information
will be obtained in the most effective manner possible.
Effective start/end date4/2/931/31/97


  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health


  • Medicine(all)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.